Stock Analysis

Exscientia First Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.38 loss in 1Q 2023)

NasdaqGS:EXAI
Source: Shutterstock

Exscientia (NASDAQ:EXAI) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$6.70m (down 5.7% from 1Q 2023).
  • Net loss: US$26.5m (loss narrowed by 43% from 1Q 2023).
  • US$0.21 loss per share (improved from US$0.38 loss in 1Q 2023).
earnings-and-revenue-growth
NasdaqGS:EXAI Earnings and Revenue Growth May 22nd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Exscientia Earnings Insights

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 8.4% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Exscientia has 4 warning signs (and 1 which doesn't sit too well with us) we think you should know about.

Valuation is complex, but we're helping make it simple.

Find out whether Exscientia is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.